A Study to Evaluate THB001 in Adult Patients With Chronic Cold Urticaria

Summary

This is a phase 1b, open label, non-randomized, sequential dose-escalation, multicenter trial in adult patients with chronic cold urticaria.

Timeline

Start

2022-09-06

Primary completion

2023-03-30

Completion

2023-04-04

Outcome

Outcome not reported

Stopped (Enrollment): “The decision to discontinue the study was made after observing moderate drug induced liver injury in two subjects enrolled in the first dose cohort.”

Drugs

Indications